Navigation Links
Unique dual target specificity of kinase inhibitor key for success against cancer

Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo. The findings, published in the May issue of Cancer Cell, shed light on which PI3 kinase family members are most likely to play a role in cancer progression. This study reinforces the concept that successful small molecule kinase inhibitors must display a broad reactivity to effectively attenuate the complex signaling pathways involved in malignant transformation and to thwart to the ability of cancer cells to adapt to stress.

Lipid kinases belonging to the PI3 kinase family, made up of different isoforms, promote cell growth and survival. Aberrant regulation and activation of PI3 kinases has been implicated in several human malignancies. Although the specific mechanisms and PI3K-associated molecules involved in cancer are not clear, this kinase family represents a rational and promising target for design of new cancer therapeutics. Dr. William A. Weiss, from the Department of Neurology at the University of California, San Francisco and coworkers sought to identify which PI3 kinase isoforms are critical for growth and progression of malignant glioma cells. UCSF colleagues Zachary Knight and Kevan Shokat synthesized and characterized a series of novel inhibitors that span the different PI3 kinase isoforms (described in the May issue of Cell). Qi-Wen Fan in the Weiss lab screened these agents in glioma cell lines. One compound, PI-103, uniquely and potently blocked the growth of glioma cells.

The cellular activity of PI-103 was traced to its ability to cooperatively inhibit both the p110รก subunit of PI3 kinase and a downstream molecule called mTOR that also plays a critical role in cell growth. Although both of these molecules are members of the same signaling cascade, the researchers found that they must be concurrently inhibited because of a regulatory feedback loop that renders a monospecific inhibitor ineffect
'"/>

Source:Cell Press


Page: 1 2

Related biology news :

1. Breast Cancer May Be Uniquely Sensitive To Inhibitors Of PI3K Pathway
2. Unique library of plant genes germinates, takes root at UNC
3. Invitrogen Launches i-Path -- A Unique Systems Biology Platform at BIO 2005
4. Uniquely human component of language found in gregarious birds
5. Unique equine cataract surgery offered on routine basis
6. Unique soybean lines hold promise for producing allergy-free soybeans
7. Unique gene regulation gives chilly bugs survival advantage at bottom of the world
8. Unique tomatoes tops in disease-fighting antioxidants
9. New binding target for oncogenic viral protein
10. Ancient olfaction protein is shared by many bugs, offering new pest control target
11. A bacterial genome reveals new targets to combat infectious disease

Post Your Comments:
(Date:11/4/2009)...s out, hold the power to help militaries and munit...p toxic waste on test sites. , Compounds known a... in World War II and have been used in military mu...are often used to propel tank shells and act like ...reased knowledge of their environmentally harmful ...
(Date:11/4/2009)...s received more than $10 million in research grant...l stimulus program, bringing thetotal amount of st...illion. Thirty-three projects achieved stimulus f...ther. , "The university has thoughtfully underta...larly excellence to federal agency priorities. Th...
(Date:11/4/2009)...FirstCall/ -- Quest Diagnostics Incorporated (NYSE...ic testing, information and services, announced th... income from continuing operations rose to $192 mi...on, or $0.81 per diluted share, for the third quar...educed by a $0.03 per share charge associated with...
Breaking Biology News(10 mins):Genomic research will enable greener cleanup of military explosive test sites 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 4Quest Diagnostics Reports Strong Performance in Third Quarter 2009 5Quest Diagnostics Reports Strong Performance in Third Quarter 2009 6Quest Diagnostics Reports Strong Performance in Third Quarter 2009 7Quest Diagnostics Reports Strong Performance in Third Quarter 2009 8Quest Diagnostics Reports Strong Performance in Third Quarter 2009 9Quest Diagnostics Reports Strong Performance in Third Quarter 2009 10Quest Diagnostics Reports Strong Performance in Third Quarter 2009 11Quest Diagnostics Reports Strong Performance in Third Quarter 2009 12Quest Diagnostics Reports Strong Performance in Third Quarter 2009 13Quest Diagnostics Reports Strong Performance in Third Quarter 2009 14Quest Diagnostics Reports Strong Performance in Third Quarter 2009 15Quest Diagnostics Reports Strong Performance in Third Quarter 2009 16Quest Diagnostics Reports Strong Performance in Third Quarter 2009 17Unprecedented Merger Occurs in Retained Physician Search Industry 47441 1Unprecedented Merger Occurs in Retained Physician Search Industry 47441 2Unprecedented Merger Occurs in Retained Physician Search Industry 47441 3Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 1Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 3Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 4Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 5Religious devotion does not impact abortion decisions of young unwed women 47440 1Religious devotion does not impact abortion decisions of young unwed women 47440 2
...ng held by plants has been revealed by Howard Hugh...y, which builds on more than a decade of painstaki...different types of plant tissues, shows clearly fo...e research, conducted by Sigal Savaldi-Goldstein a...anne Chory at The Salk Institute for Biological St...
... at Johns Hopkins have discovered how cells fine-t...nt is available at the moment. , Too little oxygen...power it, so when oxygen is scarce, cells appear t...fficient substitute that "is specialized to keep t... out of gas," says Gregg Semenza, M.D., Ph.D., a p...
...ndred years after the first vitamin was named, wha...ficial, standardized recommendations for public he...or, and director of the Nutrition and Neurocogniti...on Research on Aging (USDA HNRCA) at Tufts Univers...titutes of Health State-of-the- Science Conference...
Other Biology News:Researchers learn what sparks plant growth 2Researchers learn what sparks plant growth 3Need oxygen? Cells know how to spend and save 2Vitamins: Science doesn't always match policy 2
(Date:11/5/2009)... ThermoGenesis Corp. (Na...oducts for processing and storing adult stem cells...fiscal 2010. ,, For the quarter ended September...illion, a 15 percent increase over revenues of $4....pany said the key contributors to the growth in re...
(Date:11/5/2009)...wire-FirstCall/ -- BioSpecifics Technologies Corp....eloping first-in-class collagenase-based products,...rd quarter ended September 30, 2009. ,, "We we..., the FDA,s Arthritis Advisory Committee unanimous... XIAFLEX(TM) for the treatment of Dupuytren,s dise...
(Date:11/5/2009)...9 Senomyx, Inc. (Nasdaq:...aste receptor-based technologies to discover novel...gredient supply industries, today provided a corpo... third quarter ended September 30, 2009. Revenues...compared to $4.0 million for the third quarter of ...
(Date:11/5/2009).... 5 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Co..."Company") today announced,that the Company plans ...,Monday, November 9, 2009, after the market closes...ll at 5:00 pm ET on November 9, 2009,to discuss th...e call by,dialing 1-888-713-4211 or 1-617-213-4864...
Breaking Biology Technology:ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14BMP Sunstone to Report Third Quarter 2009 Financial Results 2
...rushing into the adoption of electronic medical re...cern for data security? , ,The question has been r...e some bills seek to provide incentives to encoura...ords, and others that raise privacy concerns are c...Moreover, headline-grabbing data breaches in both ...
...Corp. has been awarded a Phase II SBIR grant wort...logy for clinical research and possible diagnostic...nce company engaged in gene therapy and the study ...rom the National Institute of General Medical Sci...ween Mirus Bio scientist Mary Anne Watt and Gregor...
...al knows the missing link in many software evaluat...the implementation. , ,Cagigal, chief information ...d technologists who miscalculate return on investm... costs, which will exceed the implementation cost ...al It,s easy to pinpoint the pre-implementation c...
Other Biology Technology:Privacy, trust still the biggest barriers to electronic record sharing 2Privacy, trust still the biggest barriers to electronic record sharing 3The business case for software applications 2The business case for software applications 3
Mouse Anti-Human Relaxin-2, pro- Monoclonal Antibody, Unconjugated, Clone fred from Immundiagnostik
Rabbit Anti-Chicken IgY, IgG F(ab')2 fragment Antibody, Rhodamine Conjugated from Biomeda Corporation
Goat Anti-Human Presenilin 2 Antibody, Unconjugated from ABR-Affinity BioReagents
Anti-TWIK-2 (Kcnk6, TOSS) Polyclonal Antibody, Unconjugated from CHEMICON
Biology Products: